Bausch + Lomb to acquire ISTA Pharmaceuticals

Article

Bausch + Lomb has signed an agreement to acquire ISTA Pharmaceuticals for about $500 million, the companies jointly announced March 26.

Madison, NJ and Irvine, CA-Bausch + Lomb (B+L) has signed an agreement to acquire ISTA Pharmaceuticals for about $500 million, the companies jointly announced March 26. ISTA is the third largest branded prescription eye-care business in the United States, with an expanding focus on allergy treatments.

A complementary union

ISTA's ophthalmic product portfolio includes the NSAID Bromday (bromfenac 0.09%); Bepreve (bepotastine besilate 1.5%) for allergy related ocular irritation; Isatol (timolol 0.5%); and Vit-rase (hyaluronidase) injection. Its product pipeline contains additional therapies for dry eye, ocular inflammation and pain, and nasal allergies, according to the joint announcement.

"ISTA is an excellent strategic fit with [B +L's] rapidly growing pharmaceutical business, and this combination represents an important step in [B+L's] commitment to becoming the best global eye-health company," said Brent Saun-ders, president and CEO, B+L.

A 'natural extension'

Saunders said that B+L already manufactures almost all of ISTA's current U.S. portfolio. "With this combination, we will significantly enhance our pharmaceutical pipeline, nearly doubling the number of mid- to late-stage innovations."

Vicente Anido Jr., PhD, president and CEO of ISTA, said the acquisition is "a natural extension" of B +L's pharmaceutical focus. "Together, we create an impressive platform to commercialize new eye-care and allergy products already under development," he said.

Share price soars

The purchase price of $9.10 a share reflects an 8% premium over the stock price of $8.38 at the close of business on the date of the announcement, and a 40% premium over the Va-leant Pharmaceuticals bid for ISTA, according to the joint announcement. The share price also is 134% higher than the share price on Dec. 15,2011, the day before ISTA announced the Valeant bid.

B+L said it would finance the acquisition with a combination of cash and a $350 million short-term loan from a consortium of banks. Both companies' boards have approved the acquisition, which is expected to close in the second quarter, according to the announcement.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Arkansas Optometric Association legislative cochairs Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD, discuss their involvement in their bill and provide context for its relevance.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Paul Karpecki, OD, FAAO
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
© 2025 MJH Life Sciences

All rights reserved.